Oramed Pharmaceuticals (ORMP) Insider Trading & Ownership $2.30 -0.01 (-0.43%) As of 01/23/2025 03:59 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Oramed Pharmaceuticals (NASDAQ:ORMP) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage13.70%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$293,240.00Number OfInsiders Selling(Last 3 Years)2Amount OfInsider Selling(Last 3 Years)$261,328.75 Get ORMP Insider Trade Alerts Want to know when executives and insiders are buying or selling Oramed Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ORMP Insider Buying and Selling by Quarter Oramed Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/16/2023Nadav KidronCEOBuy26,000$2.04$53,040.00 3/14/2023Nadav KidronCEOBuy100,000$2.01$201,000.00 3/13/2023Yadin RozovDirectorBuy20,000$1.96$39,200.00 1/3/2023Michael RabinowitzInsiderSell13,325$12.55$167,228.75 3/21/2022Kevin RakinDirectorSell10,000$9.41$94,100.00 (Data available from 1/1/2013 forward) ORMP Insider Trading Activity - Frequently Asked Questions Who is on Oramed Pharmaceuticals's Insider Roster? The list of insiders at Oramed Pharmaceuticals includes Kevin Rakin, Michael Rabinowitz, Nadav Kidron, and Yadin Rozov. Learn more on insiders at ORMP. What percentage of Oramed Pharmaceuticals stock is owned by insiders? 13.70% of Oramed Pharmaceuticals stock is owned by insiders. Learn more on ORMP's insider holdings. Which Oramed Pharmaceuticals insiders have been buying company stock? The following insiders have purchased ORMP shares in the last 24 months: Nadav Kidron ($254,040.00), and Yadin Rozov ($39,200.00). How much insider buying is happening at Oramed Pharmaceuticals? Insiders have purchased a total of 146,000 ORMP shares in the last 24 months for a total of $293,240.00 bought. Oramed Pharmaceuticals Key ExecutivesMr. Nadav Kidron Esq. (Age 50)President, CEO & Executive Chairman Compensation: $754.3kMr. David Silberman CPA (Age 40)CFO & Treasurer Compensation: $259.53kDr. Miriam Kidron Ph.D. (Age 84)Chief Scientific Officer & Director Compensation: $503.95kMr. Joshua Hexter (Age 54)Chief Operating & Business Officer Compensation: $326.94k More Insider Trading Tools from MarketBeat Related Companies REGENXBIO Insider Trading Compass Therapeutics Insider Trading Monte Rosa Therapeutics Insider Trading Korro Bio Insider Trading Neumora Therapeutics Insider Trading MBX Biosciences Insider Trading Precigen Insider Trading Olema Pharmaceuticals Insider Trading Corvus Pharmaceuticals Insider Trading Chimerix Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Small-Cap Stocks Insiders and Institutions Are Buying3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys This page (NASDAQ:ORMP) was last updated on 1/24/2025 by MarketBeat.com Staff From Our PartnersJUST RELEASED: HUGE NEW A.I. TRADEI’ve traded every major tech boom since the dawn of the personal computer. And I can tell you one thing wit...The Oxford Club | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredLegendary Investor: “Buy These “Trump Stocks Now”Within the first week of Trump's election, several stocks exploded for double- and triple-digit gains. Acco...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
